Treatment for adverse immune reaction to metal implant debris
Described herein is a method for treating or prophylaxis of adverse immune reaction to metal debris, metal induced delayed type hypersensitivity (DTH), or inflammatory osteolysis by attenuating the inflammatory response. In one aspect, the method involves inhibiting the nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) inflammasome/caspase-1 pathway or neutralizing or blocking the activity of interleukin 17 (IL-17), IL-17 receptor (IL-17R), IL-1R, IL-1β, IL-18, IL-21, IL-23 with anti-IL-17, anti-IL-17A, anti-IL-17F, anti-IL-17A/F, anti-IL-1, anti-IL-1β, anti-IL-18, anti-IL-21, anti-IL-23, anti-IL-1R, soluble IL-17 receptors, soluble IL-1 receptors, soluble IL-18 receptors, soluble IL-21 receptors, IL-17 receptor inhibitors, IL-1 receptor inhibitors, IL-18 receptor inhibitors, IL-21 receptor inhibitors, IL-23 receptor inhibitors, blocking agents, inflammasome inhibitors, or combinations thereof.
1. A method for treating an adverse immune reaction to metal debris, metal induced delayed type hypersensitivity, or inflammatory osteolysis in a subject in need thereof comprising administering an inhibitor of IL-17 activity, wherein the adverse immune reaction to metal debris, metal induced delayed type hypersensitivity, or inflammatory osteolysis is caused by orthopedic metal implant debris.
2. The method of claim 1 , wherein said inhibitor is an effective amount of one or more anti-cytokine antibodies, anti-receptor antibodies, soluble receptors, receptor inhibitors, or blocking agents to the subject.
3. The method of claim 2 , wherein the anti-cytokine antibodies, anti-receptor antibodies, soluble receptors, receptor inhibitors, or blocking agents comprise anti-IL-17, anti-IL-17A, anti-IL-17F, anti-IL-17A/F, soluble IL-17 receptors, IL-17 receptor inhibitors, or combinations thereof.
4. The method of claim 2 , wherein the anti-cytokine antibodies, anti-receptor antibodies, soluble receptors, receptor inhibitors, or blocking agents comprise secukinumab, ixekizumab, brodalumab, or combinations thereof.
5. The method of claim 2 , wherein the anti-cytokine antibodies, anti-receptor antibodies, soluble receptors, receptor inhibitors, or blocking agents, are co-administered.
6. The method of claim 2 , wherein administration of the inhibitor occurs within about 0.5 hour to about 30 days of onset of the adverse immune reaction to metal debris, metal induced delayed type hypersensitivity, or inflammatory osteolysis.
7. The method of claim 2 , wherein administration of the inhibitor comprises parenteral administration.
8. The method of claim 2 , wherein administration of the inhibitor comprises intravenous, intraarterial, intramuscular, intraarticular, intradermal, subcutaneous, or intraperitoneal administration.
9. The method of claim 2 , wherein administration of the inhibitor comprises intravenous administration.
10. The method of claim 1 , wherein the subject is a human.
11. The method of claim 1 , wherein the orthopedic metal implant debris comprises nickel, cobalt, or chromium.
12. The method of claim 1 , wherein the orthopedic metal implant is associated with total joint arthroplasty.
13. The method of claim 1 , wherein the adverse immune reaction to metal debris, metal induced delayed type hypersensitivity, or inflammatory osteolysis is identified histologically as aseptic lymphocyte-dominated vasculitis-associated lesions (ALVAL) in periprosthetic tissue.
14. A method for depleting a subject's systemic levels of IL-17 or blocking a IL-17 receptor comprising contacting IL-17 or IL-17 receptors with anti-IL-17, anti-IL-17A, anti-IL-17F, anti-IL-17A/F, anti-IL-1, anti-IL-1β, anti-IL-1R, soluble IL-17 receptors, IL-17 receptor inhibitors, or combinations thereof,
wherein the subject is experiencing an adverse immune reaction to metal debris, metal induced delayed type hypersensitivity, or inflammatory osteolysis that is caused by orthopedic metal implant debris.
15. The method of claim 14 , wherein the contacting comprises parenteral administration of one or more of anti-cytokine antibodies, anti-receptor antibodies, soluble receptors, receptor inhibitors, or blocking agents.
16. The method of claim 15 , wherein the parenteral administration comprises intravenous, intraarterial, intramuscular, intraarticular, intradermal, subcutaneous, or intraperitoneal administration.
17. A method for inhibiting IL-17 activity in a subject experiencing adverse immune reaction to metal debris, metal induced delayed type hypersensitivity, or inflammatory osteolysis by the administration of one or more anti-cytokine antibodies, anti-receptor antibodies, soluble receptors, receptor inhibitors, or blocking agents of IL-17 or IL-17 receptors to the subject,
wherein the adverse immune reaction to metal debris, metal induced delayed type hypersensitivity, or inflammatory osteolysis is caused by orthopedic metal implant debris.
18. The method of claim 17 , wherein the anti-cytokine antibodies, anti-receptor antibodies, soluble receptors, receptor inhibitors, or blocking agents comprise anti-IL-17, anti-IL-17A, anti-IL-17F, soluble IL-17 receptors, IL-17 receptor inhibitors, or combinations thereof.
19. The method of claim 17 , wherein the anti-cytokine antibodies, anti-receptor antibodies, soluble receptors, receptor inhibitors, blocking agents comprise secukinumab, ixekizumab, brodalumab, or combinations thereof.
20. The method of claim 17 , wherein the anti-cytokine antibodies, anti-receptor antibodies, soluble receptors, receptor inhibitors, or blocking agents are co-administered.
21. A method for blocking intracellular effects of IL-17 or IL-17R, in a subject, comprising administering anti-IL-17, anti-IL-17A, anti-IL-17F, anti-IL-17A/F, soluble IL-17 receptors, IL-17 receptor inhibitors, or combinations thereof, wherein the subject is experiencing an adverse immune reaction to metal debris, metal induced delayed type hypersensitivity, or inflammatory osteolysis that is caused by orthopedic metal implant debris.